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Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau
and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression
in Patients With Alzheimer Disease
Jorge J. Llibre-Guerra, MD, MSc; Yan Li, PhD; Suzanne E. Schindler, MD, PhD; Brian A. Gordon, PhD; Anne M. Fagan, PhD; John C. Morris, MD;
Tammie L. S. Benzinger, MD, PhD; Jason Hassenstab, PhD; Guoqiao Wang, PhD; Ricardo Allegri, MD; Sarah B. Berman, MD, PhD; Jasmeer Chhatwal, MD;
Martin R. Farlow, MD; David M. Holtzman, MD; Mathias Jucker, PhD; Johannes Levin, MD; James M. Noble, MD, MS; Stephen Salloway, MD; Peter Schofield, PhD;
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Abstract

Key Points

IMPORTANCE The amyloid/tau/neurodegeneration (A/T/N) framework uses cerebrospinal fluid
(CSF) levels of total tau (tTau) as a marker of neurodegeneration and CSF levels of phosphorylated
tau 181 (pTau181) as a marker of tau tangles. However, it is unclear whether CSF levels of tTau and
pTau181 have similar or different trajectories over the course of Alzheimer disease.

Question How do different proposed
measurements of tau brain pathologic
abnormalities (ie, levels of
phosphorylated tau 181 in the
cerebrospinal fluid [CSF]) and

OBJECTIVES To examine the rates of change in CSF levels of tTau and pTau181 across the Alzheimer
disease course and how the rates of change are associated with brain atrophy as measured by
magnetic resonance imaging.

neurodegeneration (ie, total tau levels in
the CSF and brain atrophy) change over
the course of Alzheimer disease?
Findings This cohort study of 465

DESIGN, SETTING, AND PARTICIPANTS This cohort study was set in tertiary research clinics. Each

participants with dominantly inherited

participant was a member of a pedigree with a known mutation for dominantly inherited Alzheimer

Alzheimer disease found that the rates

disease. Participants were divided into 3 groups on the basis of the presence of a mutation and their

of change for CSF levels of total tau and

Clinical Dementia Rating score. Data analysis was performed in June 2019.

phosphorylated tau 181 had a different
pattern across the course of Alzheimer

MAIN OUTCOMES AND MEASURES Rates of change of CSF tTau and pTau181 levels and their

disease. The association between the

association with the rate of change of brain volume.

rates of change of CSF levels of total tau
and phosphoryated tau 181 and brain

RESULTS Data from 465 participants (283 mutation carriers and 182 noncarriers) were analyzed.
The mean (SD) age of the cohort was 37.8 (11.3) years, and 262 (56.3%) were women. The mean (SD)
follow-up duration was 2.7 (1.5) years. Two or more longitudinal CSF and magnetic resonance imaging
assessments were available for 160 and 247 participants, respectively. Sixty-five percent of mutation
carriers (183) did not have symptoms at baseline (Clinical Dementia Rating score, 0). For mutation
carriers, the annual rates of change for CSF tTau and pTau181 became significantly different from 0

atrophy varied by disease stage.
Meaning These results may provide a
better understanding of the dynamics of
Alzheimer disease and have important
implications as trials targeting tau brain
pathologic abnormalities move forward.

approximately 10 years before the estimated year of onset (mean [SE] rates of change, 5.5 [2.8] for
tTau [P = .05] and 0.7 [0.3] for pTau 181 [P = .04]) and 15 years before onset (mean [SE] rates of
change, 5.4 [3.9] for tTau [P = .17] and 1.1 [0.5] for pTau181 [P = .03]), respectively. The rate of change
of pTau181 was positive and increased at the early stages of the disease, showing a positive rate of
change starting at 15 estimated years before onset until 5 estimated years before onset (mean [SE],

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

0.4 [0.3]), followed by a positive but decreasing rate of change at year 0 (mean [SE], 0.1 [0.3]) and
then negative rates of change at 5 years (mean [SE], −0.3 [0.4]) and 10 years (mean [SE], −0.6 [0.6])
after symptom onset. In individuals without symptoms (Clinical Dementia Rating score, 0), the rates
of change of CSF tTau and pTau181 were negatively associated with brain atrophy (high rates of
change in CSF measures were associated with low rates of change in brain volume in asymptomatic
stages). After symptom onset (Clinical Dementia Rating score, >0), an increased rate of brain atrophy
was not associated with rates of change of levels of both CSF tTau and pTau181.
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE These findings suggest that CSF tTau and pTau181 may have
different associations with brain atrophy across the disease time course. These results have
implications for understanding the dynamics of disease pathobiology and interpreting neuronal
injury biomarker concentrations in response to Alzheimer disease progression and disease-modifying
therapies.
JAMA Network Open. 2019;2(12):e1917126. doi:10.1001/jamanetworkopen.2019.17126

Introduction
The neuropathologic hallmarks of Alzheimer disease (AD) are the presence of neuritic amyloid
plaques, primarily of the amyloid-β peptide, and the intraneuronal accumulation of neurofibrillary
tangles (NFTs) and neuropil threads composed of hyperphosphorylated, aggregated tau protein.1,2
Our understanding of AD has evolved substantially over the past 2 decades, with neuroimaging and
fluid biomarkers allowing for early detection of AD-related pathologic abnormalities.3-5 In fewer than
1% of patients, AD is caused by autosomal dominant mutations in either the presenilin 1, presenilin
2, or amyloid precursor protein genes. Dominantly inherited AD (DIAD) is considered clinically similar
to sporadic AD except for a younger age at onset (AAO).6 Mutation carriers (MCs) have a somewhat
predictable age at AD symptom onset.7
Biomarker studies6,8 have contributed to hypothesized trajectories of fluid and imaging
biomarker changes that occur over the course of the disease, from the preclinical phase to the end
stages characterized by advanced dementia. However, models of biomarker change in AD have been
based mostly on cross-sectional data.6,9,10 More recently, many models have classified biomarkers
according to their proposed association with the biological underpinnings of the disease; the recent
amyloid/tau/neurodegeneration (A/T/N) framework11 was developed to provide a more biological
rationale to the classification of the disease. Phosphorylated tau 181 (pTau181) in the cerebrospinal
fluid (CSF) has been suggested to represent NFT pathologic abnormalities, whereas total tau (tTau) in
the CSF is thought to be a marker of neurodegeneration that is passively released with cell death or
injury.8,12 Given these putative mechanisms, it might be expected that levels of both tTau and
pTau181 would continue to become more abnormal with disease progression, as NFT pathologic
abnormalities increase and neurodegeneration accelerates. However, recent longitudinal studies13-17
from the Dominantly Inherited Alzheimer Network (DIAN) and Alzheimer’s Disease Neuroimaging
Initiative (ADNI) cohorts have challenged the linear model from previous cross-sectional studies,3,9,18
which have consistently found higher CSF levels of tTau and pTau181 as the disease progresses.
These findings highlight a need for accurate determination of the evolution of longitudinal
changes in CSF levels of tTau and pTau181 and their association with disease progression. In the
present study, we assessed the longitudinal pattern of changes in CSF levels of tTau and pTau181 and
their association with brain atrophy as measured by magnetic resonance imaging (MRI). We
hypothesized that if CSF tTau and pTau181 were passively released with neurodegeneration, they
should be associated with MRI measures of neurodegeneration (eg, rate of atrophy). To evaluate this
hypothesis, we used a well-characterized cohort with DIAD from the DIAN study.19

Methods
All participants were recruited as part of the DIAN study.20 Participants provided written informed
consent or assent with proxy consent. The institutional review boards for each of the participating
DIAN sites approved all aspects of the study. This study follows the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting guideline.
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For our analysis, 465 participants with at least 1 CSF measurement in the DIAN cohort were
available from the data freeze 12 (last data from June 30, 2017). Each participant was a member of a
pedigree with a known mutation for DIAD. Genotyping was performed to determine the genetic
status for each participant at risk; the presence or absence of a DIAD mutation was determined using
polymerase chain reaction–based amplification of the appropriate exon followed by Sanger
sequencing methods on a genetic analyzer (ABI 3130xl; ThermoFisher Scientific).21
Participants were divided into 3 groups according to the presence of a mutation and their
Clinical Dementia Rating (CDR)22 score at baseline, with a CDR score of 0 indicating no symptoms
and a CDR score of 0.5 or higher indicating the presence of symptoms. The participant’s estimated
years before expected symptom onset (EYO) was defined as the participant’s age at baseline minus
their expected AAO.6,7,23 The AAO was calculated according to either the family mutation–specific
expected age at dementia onset or parental age at first progressive cognitive decline if the expected
AAO for the mutation was unknown. Negative values indicate that an individual is younger than his
or her expected AAO.

Clinical and Neuropsychological Assessments
Participants underwent extensive clinical evaluation, which included family history of AD, personal
medical history, and physical and neurological examination. Clinical dementia status was determined
with the CDR in accordance with standard protocols and criteria.22,24 Clinicians performing the
assessments were blinded to mutation status of participants. Full details of participating sites,
enrollment, and assessments in DIAN have been published elsewhere.20

Brain Imaging
MRI Scanning
Participants underwent volumetric T1-weighted MRI, using the magnetization-prepared rapid
acquisition with gradient-echo sequence defined in the ADNI second phase.25 Sites used a 3-T
scanner and were required to pass regular quality control assessments. Volumetric segmentation and
cortical surface reconstruction were performed using FreeSurfer image analyzing software version
5.3 (Harvard Medical School),26 and subcortical volumes were corrected for intracranial volume using
a regression approach.27 Cortical thickness and volume measures were averaged across hemispheres
because there were no a priori laterality predictions. Because the focus of our study was to assess
the association between longitudinal CSF tTau and pTau181 levels with atrophy rate, a limited number
of regions of interest (ROIs) reflecting brain atrophy patterns across AD stages were included. We
followed an ROIs approach to include posterior areas with earlier tau deposition (eg, hippocampus,
entorhinal cortex, parahippocampus, posterior cingulate gyrus, precuneus gyrus, and supramarginal
gyrus) and atrophy vs anterior areas with later tau deposition (eg, superior frontal gyrus, orbital
frontal gyrus, and midfrontal gyrus) and atrophy. The ROIs were defined according to areas of early
vs late neurodegeneration and tau deposition in the literature and our previous work.3,14,28-31
Biochemical Analysis
The CSF was collected in the morning under fasting conditions by lumbar puncture and immediately
placed on ice. Samples were shipped on dry ice to the DIAN biomarker core laboratory. We have
previously reported a longitudinal decrease in CSF tTau and pTau181 levels using commercially
available immunoassays.14 To also test whether those findings were specific to the method of
measurement, here we used a fully automated, high-performance electroluminescence
immunoassay (Elecsys; Roche Diagnostics) of tTau and pTau181 in the laboratory of Leslie Shaw, PhD,
in the ADNI Biomarker Core at the University of Pennsylvania according to the kit manufacturer’s
instructions and as described in previous studies.32-34 Analyses were performed in a series of runs,
with each sample run 1 time for each of the tau analytes, over the period of October 18, 2017, through
November 9, 2017; acceptance criteria as documented according to the Roche Protocol in the
University of Pennsylvania ADNI Biomarker Laboratory were followed. In each of the 14 days of
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performing analyses, the manufacturer’s quality control results were within stated limits to meet
acceptance criteria for precision and accuracy. There were 2 runs each day of approximately 40
samples per run. Precision performance was documented according to analysis of pristine aliquots of
a CSF pool in each of the 28 runs for each of the biomarkers. The percentage coefficients of variation
for this CSF quality control pool were less than 2%.

Statistical Analysis
Data analysis was performed in June 2019. Baseline characteristics of the participants are
summarized as mean (SD) for continuous variables and number (column percentage) for categorical
variables. P values for comparing the difference between MCs and noncarriers (NCs) were obtained
using generalized linear mixed-effects models with random intercepts for family clusters to take into
account the associations between participants within the same family; the tests were 2-sided. The
annualized rate of change over the longitudinal follow-up period was estimated for each participant
separately using linear regression and then plotted against baseline EYO to evaluate the trajectories
of the biomarker changes over EYO. To visualize the differences in the rates of change of different
biomarkers as a function of EYO, locally estimated scatterplot smoothing curves of the standardized
difference of individual annual rates of change for MCs for different biomarkers were plotted against
baseline EYO. A linear or linear spline mixed-effects model for each biomarker (depending on the
curve fit) was then used to estimate and test the rates of change at each integer EYO point. The fixed
effects in the models included mutation group (MC or NC), baseline EYO, time since baseline, and all
possible 2-way or 3-way interactions. Sex, years of education, and apolipoprotein ε4 allele status
were considered as covariates, but only significant effects were retained in the models. Random
effects included in the models are random intercepts for family clusters, individual random intercept,
and random slope. An unstructured covariance matrix was used to account for the withinparticipant association due to repeated measures. Further details for the linear and linear spline
mixed-effects models can be found in the article by McDade et al.14
Associations between the individual annual rates of change of tTau and pTau181 concentrations
and the annualized rates of brain atrophy were evaluated for MCs with symptoms (CDR score, >0)
and MCs without symptoms (CDR score, 0) separately, using bivariate linear mixed-effects models
with random intercepts for family clusters.35,36 Statistical analyses were conducted with the PROC
MIXED and PROC NLMIX procedures in SAS statistical software version 9.4 (SAS Institute Inc). A
P < .05 was considered to be statistically significant. For CSF biomarkers (145 NCs and 235 MCs), the
effect size that could be detected with 80% power was 0.3. For MRI biomarkers (177 NCs and 270
MCs), the effect size that could be detected with 80% power was 0.27.

Results
We analyzed data from 465 participants, including 283 MCs (183 [65%] without symptoms and 100
with symptoms) and 182 NCs (Table 1). The mean (SD) age of the cohort was 37.8 (11.3) years, and
262 (56.3%) were women. Of the MCs, 213 (75.3%) had presenilin 1 mutations, 22 (7.8%) had
presenilin 2 mutations, and 48 (16.9%) had amyloid precursor protein mutations. There were no
differences between MCs and NCs in terms of age (mean [SD] age, 37.8 [10.8] vs 37.9 [11.7] years), sex
(55.1% vs 58.2% female), educational level (mean [SD] years, 14.3 [3.0] vs 14.8 [2.9]), or the presence
of at least 1 apolipoprotein ε4 allele (29.7% vs 30.8%). The EYO for the entire cohort ranged from
38.2 years before the parental AAO to 22.6 years after the parental AAO; however, to reduce the risk
of identifying individual participants at the extremes of the EYO range, we show only the EYO interval
of −25 to 10 years. The NCs had no or very little evidence of AD pathologic abnormalities and almost
all (171 [94.0%]) had normal cognition. At baseline, 183 MCs (64.7%) did not have symptoms
(CDR score, 0). The CDR scores of the MCs with symptoms ranged from 0.5 (very mild) to 3 (severe)
(Table 1). Two or more longitudinal CSF and MRI assessments were available for 160 and 247
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participants, respectively (Table 1 and eTable 1 in the Supplement) with a mean (SD) follow-up of 2.7
(1.5) years.

Longitudinal Change in CSF tTau and pTau181 Levels
Previous analyses14,17 of this cohort have found that CSF tTau and pTau181 levels were increased in
MCs 15 years before expected symptom onset (EYO = −15). We also examined the longitudinal
change in CSF tTau and pTau181 levels in terms of annual rate of change across the EYO (Figure 1 and
Table 2). Rates of change for NCs were not significantly different from 0. For MCs, the annual rates
of change for CSF tTau and pTau181 became significantly different from 0 near EYO −10 (mean [SE]
rates of change, 5.5 [2.8] for tTau [P = .05] and 0.7 [0.3] for pTau 181 [P = .04]) and EYO −15 (mean
[SE] rates of change, 5.4 [3.9] for tTau [P = .17] and 1.1 [0.5] for pTau181 [P = .03]), respectively
(Table 2). Importantly, the longitudinal rates of change of CSF tTau and pTau181 levels depended on
where the participant fell with respect to their EYO, and the pattern of change over the AD course
was different for tTau and pTau181. Specifically, the positive rate of change of tTau gradually
increased until EYO −10 and then remained constant after symptom onset (mean [SE] rate of change,
5.6 [2.3] for EYO 0, 5.6 [3.2] for EYO 5, and 5.7 [4.4] for EYO 10). In contrast, the positive rate of
change of pTau181 increased in those at early stages of the disease, starting at EYO −15 until EYO −5
(mean [SE], 0.4 [0.3]), followed by a positive but decreasing rate of change at year 0 (mean [SE] 0.1
[0.3]) and then negative rates of change at EYO 5 (mean [SE], −0.3 [0.4]) and EYO 10 (mean [SE],
−0.6 [0.6]) (Table 2), resulting in overall lower levels of pTau181 at later stages of disease.

Table 1. Clinical, Cognitive, Imaging, and Biochemical Characteristics of Study Participants at Baselinea
Mean (SD)
Clinical and Baseline Biomarker Characteristics

Noncarriers
(n = 182)

Mutation Carriers
(n = 283)

P Value

Age, y

37.9 (11.7)

37.8 (10.8)

.80

Female, No. (%)

106 (58.2)

156 (55.1)

.50

Education, y

14.8 (2.9)

14.3 (3.0)

.70

Mini-Mental State Examination score

29.0 (1.2)

26.9 (5.1)

<.001

0

171 (94.0)

183 (64.7)

>0

11 (6.0)

100 (35.3)

Apolipoprotein ε4 allele carrier, No. (%)

56 (30.8)

84 (29.7)

Estimated years before onset, y

−9.7 (12.2)

−8.2 (11.0)

.20

Length of follow-up, y

3.4 (1.6)

2.9 (1.5)

.03

No. of longitudinal cerebrospinal fluid assessments, No. (%)b

Clinical Dementia Rating score, No. (%)

55 (37.9)

105 (42.9)

2

38 (69.1)

69 (65.7)

3

12 (21.8)

25 (23.8)

≥4

5 (9.1)

11 (10.5)

<.001
.80

.24

Aβ42 level, pg/mL

1385 (471)

961 (623)

<.001

Ratio of Aβ42 to Aβ40

0.09 (0.01)

0.06 (0.03)

<.001

Total tau level, pg/mL

171.6 (58.5)

287.9 (159.1)

<.001

Phosphorylated tau 181 level, pg/mL

14.2 (5.3)

30.8 (22.7)

<.001

0.0109 (0.0057)

0.0518 (0.0534)

<.001

Ratio of phosphorylated tau 181 to Aβ42
c

89 (50.3)

158 (58.5)

2

63 (70.8)

96 (60.8)

3

18 (20.2)

47 (29.7)

≥4

8 (9.0)

15 (9.5)

8798 (809)

8363 (1302)

<.001

3.50 (0.30)

3.43 (0.36)

.04

Precuneus

2.38 (0.13)

2.28 (0.22)

<.001

Superior frontal

2.66 (0.13)

2.62 (0.17)

.02

No. of longitudinal MRI assessments, No. (%)

Hippocampal volume, mm3

Abbreviation: MRI, magnetic resonance imaging.
a

Continuous measures are presented as the mean
(SD). For each type of measure, the number of
individuals with at least 1 measurement is provided.
The significance of the difference between the
mutation carriers and noncarriers was calculated by
linear mixed-effects models with random intercepts
for familial clusters.

b

A total of 160 participants underwent longitudinal
cerebrospinal fluid assessments.

c

A total of 247 participants underwent longitudinal
MRI assessments.

.09

Thickness, mm
Entorhinal cortical
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Longitudinal Change in Brain Volumes
The A/T/N framework uses CSF tTau levels and/or structural MRI measurements as a marker of
neurodegeneration, so we sought to determine whether CSF tTau could be used as a suitable
biomarker to track MRI atrophy rate. For MRI measurements in MCs, the individual annual rate of
change in precuneus thickness started to show a difference from 0 approximately 20 years before
expected symptom onset (mean [SE] rate of change, −0.008 [0.003]), followed by rate of change in
hippocampal volume (mean [SE] rate of change, −53.5 [17.9]), entorhinal thickness (mean [SE] rate
of change, −0.015 [0.007]), and superior-frontal thickness (mean [SE] rate of change, −0.010
[0.004]) around EYO −15. The longitudinal rate of change for all measured brain ROI increased 5

Figure 1. Individual Annual Rate of Change of Cerebrospinal Fluid Levels of Total Tau (tTau) and Phosphorylated
Tau 181 (pTau181) and Brain Structures by Magnetic Resonance Imaging as a Function of Baseline Estimated
Years Before Onset in Mutation Carriers and Noncarriers
20

Rate of Change in pTau181 Level, pg/mL

Rate of Change in tTau Level, pg/mL
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years before symptoms appeared (EYO −5) and followed a similar trend through the disease (Table 2
and Figure 1). For all ROIs included in the analysis, the rate of change followed similar trends.
To visually compare the differences in the trajectories of the rates of change of CSF tTau and
pTau181 levels and structural MRI measures, locally estimated scatterplot smoothing curves were
constructed for the standardized rate of change as a function of baseline EYO (Figure 2). Notably,
after EYO 0, the rate of change became more negative (structures atrophied more quickly),
compared with CSF tTau levels, which continued to have a stable positive rate of change.

Association Between CSF and MRI Measures of Neurodegeneration
We found differences in nearly all posterior and limbic or paralimibic regions for associations in rates
of change with tTau and pTau181 according to stage of disease when comparing MCs without
symptoms vs those with symptoms (eTable 2 and eTable 3 in the Supplement). Figure 3 shows
patterns of correlation coefficients between the rates of change of CSF tTau and pTau181 and brain
structure stratified by the absence or presence of symptoms (CDR score of 0 vs CDR score >0) and
by posterior (early atrophy) and anterior (later atrophy) cortical or subcortical regions. In individuals
without symptoms (CDR score of 0), the rates of change of CSF tTau and pTau181 were inversely

Table 2. Estimated Annual Rate of Change of Cerebrospinal Fluid Levels of tTau and pTau181 and Structural Magnetic Resonance Imaging (Regions of Interest)
in Mutation Carriers by Estimated Years Before Onseta
tTau

pTau181

Entorhinal Thickness

Hippocampal Volume

Precuneus Thickness

Superior Frontal Thickness

Estimated
Time Before
Onset, y

Rate of
Change,
Mean (SE)

P Value

Rate of
Change,
Mean (SE)

P Value

Rate of
Change,
Mean (SE)

P Value

Rate of
Change,
Mean (SE)

P Value

Rate of
Change,
Mean (SE)

P Value

Rate of
Change,
Mean (SE)

−25

0.3 (3.8)

.94

0.1 (0.5)

.88

0.011 (0.012)

.33

5.6 (29.0)

.85

−0.004 (0.004)

.37

−0.006 (0.006)

.32

−20

2.9 (2.7)

.28

0.6 (0.3)

.09

−0.002 (0.009)

.83

−23.9 (21.7)

.27
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correlated with most brain structure measures, where higher CSF tTau levels were associated with
smaller cortical thickness. Generally, there were higher correlation coefficients for CSF tTau in the
asymptomatic phase and mostly for the posterior neocortical and allocortical (limbic) regions.
However, after symptom onset, the correlation between CSF tTau and pTau181 and brain structures
changed. The intensity of neuronal damage as measured by brain atrophy continued at an increasing
rate, whereas the rate of change of CSF tTau levels remained at a somewhat constant rate and the
rate of change of CSF pTau181 actually switched from positive to negative. These results suggest that
CSF tTau and structural brain measures have distinct patterns later in the disease course.

Discussion
The use of biomarkers has become an essential component of AD research11,37 and therapeutic trials.
The new framework from the National Institute on Aging and Alzheimer Association11 capitalizes on
the use of biomarkers for early identification of AD, which has substantial implications for early
treatment and trial enrollment. However, little work has been done regarding comparisons of
longitudinal biomarker trajectories that are currently proposed to represent similar aspects of
disease (eg, CSF tTau and MRI are both proposed as markers of neurodegeneration).38
In this study, on the basis of longitudinal data from the DIAN study,20 we evaluated the
trajectories of CSF tTau and pTau181 over the course of AD. Notably, we included a bigger sample and
used newer CSF tTau and pTau181 values generated with a fully automated, high-performance
electroluminescence immunoassay. We compared the trajectories of CSF tTau and pTau181 with the
atrophy of brain structures as measured by MRI. First, consistent with previous reports,14,39 our
study found mean concentrations of CSF tTau and pTau181 to be higher in MCs from the early stage

Figure 3. Correlation Coefficient Maps for the Individual Annual Rate of Change of Cerebrospinal Fluid Levels of
Total Tau (tTau) and Phosphorylated Tau 181 (pTau181) and Brain Structures by Clinical Dementia Rating (CDR)
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of AD, supporting the use of CSF tau as a marker of AD risk and progression. Second, we found that
the positive rate of change of CSF tTau remained constant after EYO −10, whereas CSF pTau181 had a
positive rate of change early in the disease course, which then reversed and became negative later
in the disease. This indicates that our previous results13,14 were not likely to be an artifact of the
measurement used because we used a different method for this study. Third, the associations
identified between the rates of change of CSF tTau and pTau181 with brain atrophy do not support
the assumption that CSF tTau changes follow a pattern similar to that of structural brain changes. Our
findings indicate that neither CSF tTau nor pTau181 has the same pattern of change as brain measures
and should be considered as associated but distinct biomarkers in AD. In addition, these findings
indicate that, within the current biomarker classification, tTau is an important marker of AD but may
not be the ideal marker of neurodegeneration.
Recent studies40,41 have suggested that in the presence of amyloid pathologic abnormalities,
more CSF tTau and pTau181 is released. Moreover, increased tau in CSF seems to be dependent of
amyloid deposition and occurs in the absence of tau brain pathologic abnormalities.42
Early disease stages may also be characterized by higher cellular stress43,44 and inflammation,
with higher levels of tTau and pTau181 in CSF representing a response.45 However, if CSF tTau directly
reflected neurodegeneration, it would be expected that the rate of change of CSF tTau would
increase in concert with brain atrophy during the period of maximal rate of atrophy (EYO >0). It is
possible that during disease progression and neurodegeneration, the loss of neuronal cells results in
less neuronal substrate to produce tau. Although this might account for some of the slowing in
longitudinal changes in CSF tTau that we observed, it is unlikely that the degree of
neurodegeneration is sufficient to fully explain our findings. Early elevations may also be associated
with acute neuronal membrane damage, whereas apparent later reductions reflect the death of a
smaller number of neurons that remain. Acute neuronal injury may be associated with a stronger
inflammatory response at early stages of the disease.46
The present findings challenge some previous assumptions about AD progression and its
association with both pTau181 and tTau. Contrary to the idea that tTau and pTau181 levels continue to
increase with greater neurodegeneration and the spread of NFT,47 we found evidence of a decrease
in the rate of change, arguing against the use of these measures as a reflection of a passive release
from neuronal death and NFT. These data support the relevance of CSF tTau and pTau181 as markers
of amyloid deposition and accompanying changes (eg, inflammation and neuronal membrane
damage)11; however, the complex rates of change identified here and in our previous work suggest
that using them as measures of therapeutic response requires further investigation, because levels
vary as a function of where an individual is in the neuropathological cascade. The apparent
disconnect between CSF tTau and MRI measures may reflect the fact that they are measuring
different stages of the neurodegenerative process, with CSF tTau accounting for the active phase of
neuron injury and damage, and MRI measuring the subsequent structural sequelae of the active
death process.
Our findings are consistent with previous studies15,38,48-50 of sporadic late-onset AD. Seppälä
et al,

48

in a longitudinal study in Finland, described higher levels of pTau181 level in mild cognitive

impairment stages when compared with AD dementia, whereas levels of pTau181 decreased over a
period of about 3 years. Similarly, Toledo et al38 reported a decrease in tTau in those at the dementia
stage from the ADNI cohort. More recently, in a similar analysis of ADNI participants with longitudinal
follow-up and using similar methods to determine CSF tTau and pTau181 levels (ie, automated
electroluminescence immunoassay), Sutphen et al15 reported that tTau and pTau181 showed
consistent increases in the amyloid-positive participants with normal cognition and those with mild
cognitive impairment, whereas pTau181 decreased substantially in those with AD dementia.
This study has potential implications for AD trials using tau-based therapies and other putative
disease-modifying therapies. First, during trial design, the active group and the placebo group will
have to be randomized by disease stage (according to disease severity measured using biomarkers
and the severity of cognitive impairment), because minor differences in the neurodegeneration
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cascade stage might translate into major differences in biomarker trajectories, and as a result, might
be misinterpreted as a treatment effect. Second, one must consider how to interpret changes in
biomarkers during clinical trials readout; in other words, one must consider how a successful
treatment would be expected to affect CSF tau levels or rate of change. This study, along with recent
work assessing neurofilament light chains,51,52 suggests that neurofilament light chains may be an
advantageous marker of neurodegeneration in therapeutic trials of AD.52,53

Limitations
The present study is not without limitations. First, our results are dependent on the accuracy of the
DIAN EYO and, like any measure, it is subject to error (ie, symptom onset could be a few years earlier
or later than expected [randomly]). Second, we recognize that DIAD and late-onset AD are similar
but not identical. Sporadic AD disease occurs later in life, and individuals often exhibit a wide range of
comorbidities, including vascular disease and the presence of transactive response DNA-binding
protein of 43 kDa.54-57 These differences may be associated with biomarker profiles or natural
progression, so the total generalizability of the present findings to late-onset AD will have to be
confirmed in future cohorts. Nevertheless, the results highlight the importance of gathering
longitudinal data to refine current biomarker models.

Conclusions
The results of this study support the A/T/N framework, whereby increases in CSF levels of tTau and
pTau181 are robust diagnostic markers of pathologic abnormalities and neuronal injury in early
Alzheimer disease. However, our data suggest that levels of CSF tTau and pTau181 diverge from
atrophy-based measures of neurodegeneration later in the disease. This is an important result to
consider in clinical trials targeting tau brain pathologic abnormalities. Future studies should explore
the longitudinal rate of change of CSF pTau181 levels and positron emission tomography of tau as
markers of tau brain pathologic abnormalities.
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